ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott after announcing that the first group of patients receiving cell therapy for a blindness-causing disease saw “sustained and further improvement” to their sight. The data's from a phase IIa study of their human retinal progenitor cell (hRPC) treatment for retinitis pigmentosa.
0 Comments